Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 3
2022 1
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair.
Solta A, Boettiger K, Kovács I, Lang C, Megyesfalvi Z, Ferk F, Mišík M, Hoetzenecker K, Aigner C, Kowol CR, Knasmueller S, Grusch M, Szeitz B, Rezeli M, Dome B, Schelch K. Solta A, et al. Clin Cancer Res. 2023 Nov 14;29(22):4644-4659. doi: 10.1158/1078-0432.CCR-23-1795. Clin Cancer Res. 2023. PMID: 37725585 Free PMC article.
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity.
Valencia K, Echepare M, Teijeira Á, Pasquier A, Bértolo C, Sainz C, Tamayo I, Picabea B, Bosco G, Thomas R, Agorreta J, López-Picazo JM, Frigola J, Amat R, Calvo A, Felip E, Melero I, Montuenga LM. Valencia K, et al. J Exp Med. 2022 Dec 5;219(12):e20220726. doi: 10.1084/jem.20220726. Epub 2022 Sep 28. J Exp Med. 2022. PMID: 36169652 Free PMC article.
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Tan AC, Lai GGY, Saw SPL, Chua KLM, Takano A, Ong BH, Koh TPT, Jain A, Tan WL, Ng QS, Kanesvaran R, Rajasekaran T, Kalashnikova E, Renner D, Sudhaman S, Malhotra M, Sethi H, Liu MC, Aleshin A, Lim WT, Tan EH, Skanderup AJ, Ang MK, Tan DSW. Tan AC, et al. Cancer. 2024 May 15;130(10):1758-1765. doi: 10.1002/cncr.35263. Epub 2024 Feb 29. Cancer. 2024. PMID: 38422026
Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms.
Ferencz B, Török K, Pipek O, Fillinger J, Csende K, Lantos A, Černeková R, Mitták M, Škarda J, Delongová P, Megyesfalvi E, Schelch K, Lang C, Solta A, Boettiger K, Brcic L, Lindenmann J, Rényi-Vámos F, Aigner C, Berta J, Megyesfalvi Z, Döme B. Ferencz B, et al. Cancer Immunol Immunother. 2024 May 2;73(6):114. doi: 10.1007/s00262-024-03704-7. Cancer Immunol Immunother. 2024. PMID: 38693435 Free PMC article.
Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models.
Peinado P, Andrades A, Cuadros M, Rodriguez MI, Coira IF, Garcia DJ, Álvarez-Perez JC, Baliñas-Gavira C, Arenas AM, Patiño-Mercau JR, Sanjuan-Hidalgo J, Romero OA, Montuenga LM, Carretero J, Sanchez-Cespedes M, Medina PP. Peinado P, et al. Cancers (Basel). 2020 Dec 10;12(12):3712. doi: 10.3390/cancers12123712. Cancers (Basel). 2020. PMID: 33321963 Free PMC article.
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.
Pelosi G, Bianchi F, Dama E, Simbolo M, Mafficini A, Sonzogni A, Pilotto S, Harari S, Papotti M, Volante M, Fontanini G, Mastracci L, Albini A, Bria E, Calabrese F, Scarpa A. Pelosi G, et al. Virchows Arch. 2018 Apr;472(4):567-577. doi: 10.1007/s00428-018-2307-3. Epub 2018 Feb 1. Virchows Arch. 2018. PMID: 29388013 Free article.
11 results